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Abstract
Background: HER2 expression in breast cancer correlates with increased metastatic potential, higher tumor
recurrence rates and improved response to targeted therapies. Fluorescence in situ hybridization (FISH) and
immunohistochemistry (IHC) are two methods commonly used for the analysis of HER2 in the clinic. However, lack
of standardization, technical variability in laboratory protocols and subjective interpretation are major problems
associated with these testing procedures.
Methods: Here we evaluated the applicability of reverse-transcription quantitative polymerase chain reaction
(RT-qPCR) for HER2 testing in breast cancer. We tested thirty formaldehyde-fixed and paraffin-embedded tumor
samples by RT-qPCR, FISH and IHC and analysed and compared the data from the three methods.
Results: We found that laser-captured microdissection is essential for the accurate determination of HER2
expression by RT-qPCR. When isolating RNA from total tumor tissue we obtained a significant number of false
negative results. However, when using RNA from purified cancer cells the RT-qPCR data were fully consistent with
FISH and IHC. In addition we provide evidence that ductal carcinomas might be further classified by the differential
expression of HER3 and HER4.
Conclusions: Laser-captured microdissection in combination with RT-qPCR is a precise and cost-effective diagnostic
approach for HER2 testing in cancer. The PCR assay is simple, accurate and robust and can easily be implemented
and standardized in clinical laboratories.
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Background
The epidermal growth factor receptor (EGFR) family
is involved in the regulation of cell proliferation, dif-
ferentiation and survival [1, 2]. The family consists
of four genes that have evolved from a single ances-
tor (HER1 or EGFR; HER2/Neu or ERBB2; HER3 or
ERBB3, and HER4 or ERBB4). Functional aberrations
of HER family members have been causally linked to
the pathogenesis of a variety of human cancers in-
cluding lung, colon, breast and ovarian carcinomas
[3–5].
Approximately twenty percent of all breast cancers
exhibit an amplification and overexpression of the
HER2 gene [6]. Overexpression of HER2 can confer a
selective growth and survival advantage on cancer
cells and cause a more aggressive breast cancer
phenotype [7]. Elevated expression of HER2 has been
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associated with poor prognosis including increased
metastatic burden and higher recurrence and mortal-
ity rates, diminished response to anti-hormone and
doxorubicin-based chemotherapy and increased sensi-
tivity to anthracycline- and taxane-based chemother-
apy [8–13]. Targeted inhibition of HER2 with
trastuzumab (HerceptinTM; Genentech), pertuzumab
(Perjeta®, Genentech/Roche) or lapatinib (Tykerb™,
GlaxoSmithKline) has significantly improved clinical
outcome, both in the metastatic and in the adjuvant
settings [14–21]. Only patients whose tumors overex-
press HER2 benefit from the treatments whereas low
HER2 levels indicate non-responsiveness. As a conse-
quence the accurate quantification of HER2 expres-
sion in breast cancer is critical for selecting the right
therapy and optimizing clinical treatment modalities
[22–24].
Elevated HER2 protein levels are tightly associated
with gene amplification. As a result HER2 status is
commonly analyzed by fluorescence in situ
hybridization (FISH) [25–30]. Alternatively HER2 pro-
tein levels can be semi-quantitatively assessed by im-
munohistochemistry (IHC) [25, 31, 32]. The rates of
concordance between IHC and FISH range from
eighty to ninety percent [23, 33, 34]. FISH has been
reported to be more accurate, reproducible and ro-
bust than IHC [35]. However both assays are subopti-
mal and significant variability can arise from the lack
of standardization in tissue sampling and handling,
antibody diversity, chromosome 17 and CEP17 het-
erogeneity, instrument calibration and observer sub-
jectivity [23, 36, 37]. Determination of HER2 mRNA
levels by real-time polymerase chain reaction (qPCR)
has been suggested as simple and cost-effective alter-
native to FISH and IHC [38]. The procedure can be
fully automated, standardized and performed on small
samples and biopsies. However to this day compara-
tively few studies have evaluated the clinical applic-
ability of RT-qPCR for HER2 testing. The available
data are conflicting and range from weak to high
concordance rates with FISH and IHC [38–44]. One
drawback of previous studies was that mRNA has
mostly been isolated from whole tumor tissues. Abundance
of non-tumorigenic stroma cells might significantly influ-
ence the overall sensitivity of the assay and yield false nega-
tive results [41, 45]. Here we assessed the HER2 status in
thirty ductal carcinomas of the breast by FISH, IHC and
RT-qPCR. We could demonstrate a high concordance be-
tween the three approaches when using microdissected,
formaldehyde-fixed and paraffin-embedded (FFPE) tissue
for RNA isolation. Moreover we could detect highly vari-
able expression of HER3 and HER4 suggesting that both
could be used as additional markers for refining predictions
on prognosis and treatment response.
Methods
Formaline-fixed and paraffin-embedded (FFPE) tissue
samples and laser-captured microdissection
Standard FFPE sectioning was performed with the Leica
microtome RM 2255. For laser-captured microdissection
5 μm FFPE sections were prepared and mounted onto
Leica FrameSlides (PET-Membrane 1.4 μm, Leica). The
dried slides were subjected to a quick protocol of
haematoxylin/eosin staining: the samples were incubated
in xylene for 5 s, in 96 % ethanol for 30 s, in 70 % etha-
nol for 20 s, in ddH2O for 20 s, in haematoxylin for
55 s, in ddH2O for 30 s, in HCl-ethanol for 15 s, in
ddH2O for 20 s, in 80 % ethanol for 30 s, in eosin for
20 s, in 96 % ethanol for 25 s, in 100 % ethanol for 25 s
and finally in xylene for 30 s. Tumour regions (~10 000
cells) were selected and laser cut (CryLaS FTSS 355-50,
Leica) under a Leica DM6000B microscope. The study
was performed according to international and regional
ethical guidelines and was approved by the ethics com-
mission of Lower Austria and the Danube University
Krems, Austria (No. EK GZ 01/2015-2018).
Immunohistochemistry (IHC)
For the immunohistochemical HER2 staining, FFPE tis-
sue sections were prepared and stained using the Dako
Autostainer Universal Staining System (Dako). 2.5 μm
thick sections of the FFPE samples were prepared and
mounted onto silated microscopy slides (HistoSil slides,
Stölzle-Oberglas). The dried slides were deparaffinated
and rehydrated by immersion in xylene followed by
immersion in ethanol of decreasing concentration (96 %,
80 %, 70 %). Epitope demasking was performed in a boil-
ing citrate buffer pH 6 (Dako REALTM Target Retrieval
Solution, Dako). Staining for HER2 was performed using
a rabbit polyclonal antibody directed against ERBB2/
HER2 (Dako, A0485) diluted 1:500 in the EnVisionTM
FLEX Antibody Diluent (Dako). As a secondary antibody
a horseradish peroxidase coupled polymer (EnVision+,
Dako) was applied, which reacts with the substrate
chromogen 3,3′-diaminobenzidinetetrahydrochloride
(Liquid DAB+, Dako). Counterstaining for nuclei was
performed using haematoxylin (Dako).
Fluorescent in situ hybridization (FISH)
FISH was performed on 4 μm thick FFPE sections
immobilized on silated glass microscopy slides (HistoSil
slides, Stölzle-Oberglas). Staining was perfomed using
the Vysis TOP2A/HER2/CEP 17 FISH Probe Kit
(Abbott) following the manufacturer’s instructions. The
pretreatment conditions were slightly changed, using a
citrate buffer pH 6 (Gatt-Koller) for 70 min at 80 °C in-
stead of a Na-SCN solution. Fluorescent signals were
analysed under a Leica DM6000B microscope. FISH data
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were evaluated according to the ASCO/CAP guidelines
(http://www.asco.org/).
RNA extraction and reverse transcription (RT)
Total RNA was extracted from total tumor tissue sec-
tions or from microdissected (laser-captured) samples
yielding only cancer cells. The RNeasy FFPE kit includ-
ing an on-column DNase I digestion (Qiagen; version
09/2011) was used for RNA extraction according to the
manufacturer’s instructions. For deparaffinization the
FFPE tissue sections were treated with xylene.
Reverse transcription was performed using total RNA
according to the combined random hexamer and oli-
go(dT) priming protocol of the Transcriptor First Strand
cDNA Synthesis Kit (Roche) in a final volume of 20 μl.
Control reactions containing RNA but no reverse tran-
scriptase were tested negative for genomic DNA con-
tamination by qPCR.
Real-time quantitative PCR (qPCR)
Gene expression was assessed by RT-qPCR with
eukaryotic translation elongation factor 1 alpha 1
(EEF1A1) as endogenous control gene. For target gene
quantification pre-designed TaqMan® Gene Expression
Assays (EGFR: Hs01076093_g1, HER2: Hs01001580_m1,
HER3: Hs00176538_m1 and HER4: Hs00955525_m1;
Life Technologies) were used. Whereas the target gene
probes were labeled with 6-carboxyfluorescein (FAM),
the EEF1A1 probe was labeled with Cy5 at the 5′-end
and with a black-hole quencher (BHQ2) at the 3′-end
(MWG Eurofins) in order to allow simultaneous quanti-
fication of EEF1A1 and HER2 in one reaction (duplex
reaction). The duplex qPCR reaction mix contained a
final volume of 15 μl Taqman® Gene Expression Master-
mix (Life Technologies), HER2 Taqman® Gene Expres-
sion Assay, 600 nM EEF1A1 primers (MWG Eurofins),
200 nM EEF1A1 probe and 1 μl of cDNA. For HER1,
HER3 and HER4 singleplex reactions were performed
containing Taqman® Gene Expression Mastermix (Life
Technologies), Taqman® Gene Expression Assay, and
1 μl of cDNA. Samples were measured in triplicates. All
reactions were pipetted in rotor discs-100 using the Qia-
gility automated pipetting system (Qiagen). All qPCRs
were run on a Rotor-Gene Q (Qiagen) using the follow-
ing cycling conditions: 10 min at 95 °C for initial de-
naturation followed by 45 cycles of 95 °C for 20 s and
60 °C for 1 min. Data were analysed using the Rotor-
Gene Q Series Software (Qiagen) and relative target gene
expression levels were calculated according to the com-
parative Cq method [46]. Gene expression levels of the
target genes were calculated relative to the endogenous
control gene and depicted as relative expression levels in
arbitrary units (AU).
Statistical analysis of RT-qPCR data
For the classification of tumors with respect to HER2-,
HER3- and HER4 mRNA levels we determined cut-off
values using the algorithm developed by Budczies et al.,
at the Charité Universitätsmedizin Berlin [47]. The stat-
istical relevance of the difference between HER2 positive
and HER2 negative samples and correlations among
HER2, HER3 and HER4 expression was analysed with
the Mann-Whitney test (two-tailed) using GraphPad
Prism (version 6.03 for Windows, Graphpad Software,
www.graphpad.com).
Results
The HER2 status in breast cancer is commonly tested by
IHC and FISH. Both methods have been approved by
the US Food and Drug Administration for HER2 testing
in clinical laboratories [23]. The applicability of RT-
qPCR for HER2 assessment has not been fully estab-
lished yet. In the present study we directly compared the
performance of IHC, FISH and RT-qPCR using thirty
formaldehyde-fixed and paraffin-embedded (FFPE)
ductal carcinoma samples selected from the archive. Ac-
cording to FISH and IHC twenty samples tested negative
and ten positive for HER2 (Table 1). Grading of IHC as-
says was based on a 0, 1+, 2+ and 3+ scoring system
[20]. FISH was scored positive when the HER2/CEP17
ratio exceeded 2.2 [17, 21]. Representative images of
each group are shown in Fig. 1.
For RT-qPCR the RNA was isolated from two different
sources. First RNA was harvested from whole FFPE
tumor tissue. Second RNA was isolated exclusively from
cancer cells after separating cancer cells from the tumor
stroma by laser-captured microdissection. Both RNA
fractions were subsequently processed for HER2 specific
RT-qPCR. HER2 mRNA levels were normalized to the
expression of the endogenous control gene EEF1A1
using the comparative Cq method [46]. Independent
classification into HER2 positive and negative tumors
was performed using the publicly available cut-off finder
algorithm [47] (http://molpath.charite.de/cutoff ). When
RNA was isolated from total tumor tissue we could
detect seven tumors with elevated HER2 mRNA levels
(Fig. 2a). On the other hand when using laser-
captured microdissection we could identify ten tu-
mors with significantly increased HER2 mRNA ex-
pression (Fig. 2b).
In order to investigate the relationship among DNA
amplification, mRNA and protein levels we compared
the HER2 data obtained by FISH, IHC and RT-qPCR. In
total tumor tissue we detected a significant discordance
between RT-qPCR and the standard methods. Of the ten
HER2 positive tumors identified by FISH and IHC only
seven scored positive in the RT-qPCR approach when
using RNA from total tumor tissue (Fig. 3a). On the
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other hand when RNA was isolated exclusively from
cancer cells the RT-qPCR data were fully consistent with
FISH and IHC (Fig. 3b). Even though the sample size is
rather small one can conclude that RT-qPCR results in
high false-negative rates when RNA is extracted from
total tumor tissue (three out of ten). Hence laser-
captured microdissection prior to RT-qPCR strongly im-
proved the accuracy of HER2 mRNA quantification in
the tumor.
HER1, HER2 and HER3 were all implicated in the de-
velopment and progression of cancer [4, 48]. To quanti-
tatively assess the expression of HER1, HER3 and HER4
in the breast cancer samples we performed RT-qPCR
using RNA derived from microdissected FFPE tissues.
Significant but very low expression of HER1 (EGFR) was
detected only in ten percent of the tumors (Table 1).
HER4 expression could be found in around fifty percent
of the breast cancer samples (Table 1 and Fig. 4a). The
tumors could be separated into two groups expressing
either low or high HER4 mRNA levels (Fig. 4a). How-
ever, the amount of HER4 mRNA varied stochastically in
the HER2-negative and HER2-positive tumors (Table 1
and Fig. 4a ). HER3 was expressed in the majority of the
breast cancer samples. Ninety percent of the HER2-positive
and around seventy percent of the HER2-negative cells
expressed HER3 mRNA (Table 1). Analogous to HER4
Table 1 Archive samples of ductal, invasive mammary carcinoma
Sample Age Grade Stage LN HER2 IHC HER2 FISH HER2 qPCR* HER3 qPCR* HER4 qPCR* EGFR qPCR*
01 58 2 pT1b N0 0 1,0 121 46 - 5,9
02 60 3 ypT1c yN1a 0 1,1 580 - - -
03 75 2 pT1b N0 0 1,1 518 1133 215 -
04 59 2 pT1b N0 1 0,9 474 540 439 -
05 59 2 pTa - 2 1,2 632 - - -
06 70 3 pT1c N0 1 0,9 1198 - - -
07 53 2 pT1b SN0i- 1 0,9 474 680 66 -
08 68 2 pT1c N2a 1 0,9 603 1812 281 -
09 41 2 pT1c N1 1 1,0 305 341 133 -
10 74 2 pT1b NX 1 1,0 473 1020 - -
11 68 2 pT1b N0 1 1,0 358 196 107 -
12 52 2 pT2 N0 1 1,0 598 1149 - -
13 79 2 pT2 N1 1 1,0 186 204 145 -
14 50 2 pT1c N0 1 1,0 796 - - -
15 53 2 pT2 - 1 1,0 194 687 379 -
16 76 2 pT2 N2a 1 1,0 530 440 1167 -
17 67 2 pT1b N1a 1 1,0 172 186 93 -
18 81 2 pT2 N0 1 1,0 141 84 - -
19 73 2 pT1c N0 1 1,0 935 - - -
20 48 2 ypT2 yN0 1 1,0 294 - - 6,4
21 74 CIN pT1mic - 3 2,9 15109 4350 - -
22 26 3 pT2 N0 3 3,1 6241 149 59 0,6
23 34 3 pT2 N3a 3 4,1 7865 125 78 -
24 67 2 pT1c N1b 3 4,3 44849 406 120 -
25 65 2 ypT2 N2a 3 5,3 12160 1053 - -
26 59 2 pT1c N0 3 5,4 10934 159 - -
27 66 3 pT2 N1a 3 6,0 11866 175 - -
28 49 DCI III pT1mic - 3 2,3 12609 - - -
29 82 2 pT3 NX 3 2,4 4541 6157 - -
30 68 2 pT4d N2a 3+ 2,8 4019 5554 720 -
LN lymph node pathology
*relative expression of HER-family members in arbitrary units (RT-qPCR using RNA from laser-captured microdissection)
-: below the detection limit
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we could separate the tumors into either low or high HER3
expressing subpopulations (Fig. 4b). Interestingly all HER2
negative cancer cells showed also low HER3 expression. On
the other hand in the HER2- positive samples we could de-
tect a significant fraction of tumors that additionally
expressed very high levels of HER3 mRNA (Fig. 4b and
Table 1).
Discussion
Personalized oncology is expected to significantly im-
prove patient care and disease outcome in the near
future [49]. Precision therapy requires biomarkers to
select the right patients for the right treatment [50,
51]. Technological advances in genomics, proteomics
and systems biology have identified a large number of
biomarkers with potential clinical value [52–54]. This
wealth of information needs to be translated to the
clinic. Translation and clinical validation requires ex-
perimental tools that allow the accurate and simultan-
eous analysis of a large number of biomarkers.
Genetic testing is superior to immunological and pro-
tein- or cell-based technologies [53, 55–57]. Nucleic
acids are easily accessible and can be isolated in suffi-
cient quantity and quality from small amounts of ar-
chived FFPE samples or biopsies. qPCR is presently
the gold standard method for assessing genetic bio-
markers. Precise mutational analysis or quantification
of gene expression can be performed in a standard-
ized and automated manner. As a consequence the
clinical validation of RT-qPCR methods for biomarker
assessment is of prime importance in personalized
oncology.
Fig. 1 Representative images of HER2-negative and HER2-positive breast cancer specimen. a Tumor sections were subjected to IHC using HER2
specific antibodies and were counterstained for nuclei using haematoxylin (blue). Brown colour indicates subcellular localization of HER2. b
Determination of HER2 amplification by FISH. Specific probes for HER2 (green) TOP2A (orange) and CEP-17 (blue) were used. The nuclei were
selectively stained with DAPI
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The HER2 biomarker is instrumental for selecting
breast cancer patients that respond to the targeted
HER2 inhibitors trastuzumab, pertuzumab and lapatinib
[22, 51]. Despite the clinical importance of HER2 the
present diagnostic methods for its detection in the
tumor are only semi-quantitative, difficult to standardize
and prone to subjective interpretation [23]. Here we ana-
lysed the applicability of RT-qPCR for the accurate
quantification of HER2 expression in breast cancer.
When isolating the RNA from total tumor tissue we
found that RT-qPCR gives rather high false-negative re-
sults. In line with these findings concerns have also been
raised by other groups regarding the sensitivity and ac-
curacy of the qPCR approach [41, 45]. However, when
combining RT-qPCR with laser-captured microdissec-
tion we could demonstrate that RT-qPCR is fully
consistent with FISH and IHC. The focused isolation of
RNA from cancer cells significantly improved the sensi-
tivity and accuracy of the qPCR approach.
Signaling by HER family members is a complex and
highly integrated network with crosstalk, redundancy
and feedback controls and interactions with different ef-
fector molecules [4]. Overexpression of different mem-
bers and complex homo- and heterodimerization is
likely to influence the clinical efficacy of targeted HER
inhibitors. Here we additionally examined the expression
of HER1 (EGFR), HER3 and HER4 in the breast cancer
samples by RT-qPCR.
HER1 mRNA levels were extremely low and expres-
sion was found in a small fraction of the samples. This is
consistent with previous IHC studies that demonstrated
HER1 overexpression in only a subset of ductal breast
Fig. 3 Assessment of HER2 status using RT-qPCR, FISH and IHC. Relative expression levels of HER2/EEF1A1 in arbitrary units (AU) were calculated
for (a) total tumor tissue and (b) microdissected tumor tissue and compared to the HER2 status as determined by IHC and FISH. Mean values and
the 95 % confidence interval for the mean is separately indicated for HER2- positive and negative samples. Significantly higher HER2 mRNA levels
were detected in IHC/FISH HER2-positive samples with p < 0.001 and p < 0.0001 for total FFPE tissue and microdissected FFPE tissue, respectively
Fig. 2 HER2 mRNA levels in breast cancer specimen. Expression levels of HER2 relative to the endogenous control gene EEF1A1 in arbitrary units
(AU) (a) Total FFPE tissue (b) microdissected FFPE tissue. HER2- negative and positive samples were identified using the publicly available cutoff
finder algorithm [47]
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carcinomas [58]. HER4 was expressed in approximately
fifty percent of the tumors, and expression levels varied
irrespective of whether HER2 was present or not. Previ-
ous data on HER4 in breast carcinoma are conflicting.
There is evidence that the receptor is a negative regula-
tor of cell proliferation [4]. In some studies HER4 ex-
pression has been directly correlated to improved overall
survival and diminished tumor grade, metastasis and dis-
ease recurrence [4]. Here we could not detect any sig-
nificant correlation between HER4 expression and
tumor differentiation, size or metastatic potential.
HER3 is the preferred hetero-dimerization partner of
HER2 in different cancer types [48]. The HER2-HER3
heterodimer was found to be critically involved in tumor
initiation and progression and is considered the most ac-
tive signalling dimer of the HER family in cancer [48, 59,
60]. In our study we could identify two distinct tumor
populations that expressed either high or low levels of
HER3. Interestingly the highest expression of HER3 was
detected in the HER2 positive samples. Overexpression
of both HER2 and HER3 might critically influence onco-
genic signalling, oncogene addiction and responsiveness
to drugs targeting HER and HER-related RTKs. Presently
we are planning a large-scale retrospective study for
assessing the clinical usability of HER biomarker profiles
for predicting therapy response and patient outcome in
ductal carcinomas of the breast and in non-small cell
lung cancer.
In the future advances in high-throughput PCR and
massive parallel sequencing will allow the cost-effective
analyses of genetic alterations in cancer cells on a larger
scale [61, 62]. Massive parallel sequencing can provide
both, information on mutations and genetic rearrange-
ments as well as gene expression (mRNA) levels [63,
64]. These technologies will facilitate the analysis of the
genetic make-up of a large panel of genes at a time and
thus will have a strong impact on clinical decision mak-
ing, including the determination of familial predisposi-
tions, cancer subclasses, cancer progression, prognosis,
therapy selection and tumor recurrence [61]. For the
genetic analyses only few cancer cells are necessary mak-
ing it also an ideal tool for the molecular
characterization of circulating cancer cells in the periph-
eral blood. Massive parallel sequencing will be possible
without amplification of the DNA or RNA in the near
future [65, 66]. Thus the cost-effective and routine ana-
lyses of large gene panels or whole genomes and tran-
scriptomes will be feasible in the clinic on a daily basis.
However, when using mRNA levels as indicators for pro-
tein expression pilot studies are necessary for each sig-
naling molecule in order to demonstrate a clear
correlation between RNA and protein amounts in differ-
ent cancer types. Here we could demonstrate that the
expression of HER2 mRNA and protein levels were only
matching when mRNA was isolated specifically from
cancer cells after laser-captured microdissection of
ductal carcinomas of the breast. Laser-captured micro-
dissection can easily be standardized and implemented
into daily clinical practice and yields mRNA of sufficient
quality for qPCR or quantitative sequencing [67]. In
addition it offers the advantage for analyzing subpopula-
tions of cancer cells in the tumor to determine tumor
heterogeneity and cancer stem cell properties. Both
might be critical determinants for therapy selection,
treatment success and tumor recurrence.
Conclusion
Considering the present data we suggest that laser-
captured microdissection in combination with RT-qPCR
is an accurate diagnostic approach for HER2 testing in
cancer. In contrast to FISH and IHC the qPCR-based as-
says are simple, accurate and robust, easily standardized
Fig. 4 Relative HER4 and HER3 mRNA levels in breast cancer specimen. a HER3- and (b) HER4-high (open circles) and -low (filled circles) expressing
tumors were identified using the cutoff algorithm [47]. The differences between high and low HER3 and HER4 expression are significant with
p < 0.01 for HER3 and p < 0.001 for HER4
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and automatized and display high sensitivity, specificity
and reproducibility. However, additional and larger clin-
ical studies are needed to fully validate the value of RT-
qPCR for the assessment of HER family members in
cancer.
The clinical validation of genetic biomarkers is of
prime importance in oncology. Large numbers of vali-
dated genetic markers could be simultaneously tested in
large-scale studies using high-throughput qPCR or
massive parallel sequencing technologies. Comprehen-
sive and multi-parametric genetic profiling of tumors
will further advance personalized medicine, improve the
efficacy of targeted therapeutics and decrease morbidity
and mortality rates in cancer.
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